Breaking News Instant updates and real-time market news.

CELG

Celgene

$100.63

0.53 (0.53%)

07:41
10/14/16
10/14
07:41
10/14/16
07:41

Celgene pipeline broader and stronger than ever, says Canaccord

Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$100.63

0.53 (0.53%)

09/12/16
PIPR
09/12/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer says Celgene GED-0301 data 'vague'
Piper Jaffray analyst Joshua Schimmer says he remains skeptical on the profile of Celgene's GED-0301 for Crohn's disease. This morning's "vague press release doesn't help despite the company's expressed confidence," Schimmer tells investors in a research note. He notes that while GED-0301 is not a relevant driver of his investment thesis, the drug is important to sentiment overall. The analyst reiterates an Overweight rating on Celgene.
09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.

TODAY'S FREE FLY STORIES

09:05
09/20/17
09/20
09:05
09/20/17
09:05
General news
U.S. equities are stuck in the Fed's headlights »

U.S. equities are stuck…

SGMS

Scientific Games

$43.10

1.05 (2.50%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Scientific Games to acquire NYX Gaming Group for C$2.40 per share »

Scientific Games and NYX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

PG

Procter & Gamble

$94.17

1.02 (1.10%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Trian: Initiatives will make P&G 'best-in-class company once again' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$52.09

-4.48 (-7.92%)

09:03
09/20/17
09/20
09:03
09/20/17
09:03
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Breaking Hot Stocks news story on Rent-A-Center »

Rent-A-Center says August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$13.63

0.18 (1.34%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
American Eagle to expand to India through licensed stores »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

, GOOG

Alphabet

$921.81

6.81 (0.74%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Periodicals
Google said to acquire certain HTC assets, VentureBeat's Bass reports »

VentureBeat reporter Evan…

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Rent-A-Center reports core U.S. SSS down 5.3% in August »

Rent-A-Center, announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

09:01
09/20/17
09/20
09:01
09/20/17
09:01
Conference/Events
Meet Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EDVMF

Endeavour Mining

$18.42

-0.0721 (-0.39%)

09:00
09/20/17
09/20
09:00
09/20/17
09:00
Conference/Events
Endeavour Mining holds a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Hot Stocks
General Mills says cereal sales improved in August »

Expects to improve yogurt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CIEN

Ciena

$22.08

-0.26 (-1.16%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
Ciena analyst commentary  »

Ciena FY18 growth more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

FDX

FedEx

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

BPMC

Blueprint Medicines

$63.86

0.98 (1.56%)

08:56
09/20/17
09/20
08:56
09/20/17
08:56
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.86

0.16 (0.65%)

, S

Sprint

$8.20

0.52 (6.77%)

08:55
09/20/17
09/20
08:55
09/20/17
08:55
Options
Notable open interest changes for September 20th »

Tuesday's total…

BAC

Bank of America

$24.86

0.16 (0.65%)

S

Sprint

$8.20

0.52 (6.77%)

T

AT&T

$38.21

0.79 (2.11%)

BABA

Alibaba

$180.07

0.09 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

  • 16

    May

RARE

Ultragenyx

$51.90

-1.09 (-2.06%)

08:54
09/20/17
09/20
08:54
09/20/17
08:54
Conference/Events
Ultragenyx has a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

WBC

Wabco

$146.87

3.9 (2.73%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Conference/Events
Wabco holds a conference call »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

, TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

FSLR

First Solar

$48.86

0.32 (0.66%)

IMMU

Immunomedics

$11.64

0.38 (3.37%)

JCP

J.C. Penney

$3.97

-0.18 (-4.34%)

IYR

DJ US Real Estate Index Fund

$81.01

-0.63 (-0.77%)

CHK

Chesapeake

$4.04

-0.01 (-0.25%)

SMH

Market Vectors Semiconductor

$92.60

0.24 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Technical Analysis
Technical View: FedEx trades lower after results and outlook »

Shares were last at $213…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Recommendations
Gemphire Therapeutics analyst commentary  »

Gemphire data support…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FDX

FedEx

$216.00

0.92 (0.43%)

08:42
09/20/17
09/20
08:42
09/20/17
08:42
Recommendations
FedEx analyst commentary  »

FedEx price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.